3.5.1.92: pantetheine hydrolase
This is an abbreviated version!
For detailed information about pantetheine hydrolase, go to the full flat file.
Word Map on EC 3.5.1.92
-
3.5.1.92
-
cysteamine
-
pantothen
-
gpi-anchored
-
ectoenzyme
-
pantothenamides
-
gelatinase-associated
-
walter
-
aminothiol
-
pantethine
-
biotinidase
-
julius
-
medicine
-
diagnostics
-
drug development
- 3.5.1.92
- cysteamine
-
pantothen
-
gpi-anchored
-
ectoenzyme
- pantothenamides
-
gelatinase-associated
-
walter
-
aminothiol
- pantethine
- biotinidase
-
julius
- medicine
- diagnostics
- drug development
Reaction
Synonyms
GPI-80, PAGEL, pantetheinase, pantetheinase-associated gene expressed in leukocytes, pantetheinases, pantetheine hydrolase, vanin, vanin 1, vanin gene family, vanin-1, vanin-1 pantetheinase, vanin-2, vanin-3, vascular non-inflammatory molecule-1, vascular noninflammatory molecule 1, VNN-1, VNN1, Vnn1 pantetheinase, VNN2, VNN3
ECTree
3.5.1.92 pantetheine hydrolaseAdvanced search results
results (
results (Inhibitors
Inhibitors on EC 3.5.1.92 - pantetheine hydrolase
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
top
INHIBITOR 
ORGANISM
UNIPROT
COMMENTARY 
LITERATURE
IMAGE
2,3-bis[(2-hydroxyethyl)thio]-1,4-naphthoquinone
-
i.e. NSC 95397, from library of pharmacologically active compounds, LOPAC
2-Nitro-5-thiocyanobenzoate
-
0.1 mM, 15 min, 10% residual activity in absence of substrate S-pantetheine-3-pyruvate, 51% residual activity in presence of the substrate S-pantetheine-3-pyruvate
5,5'-dithiobis(2-nitrobenzoate)
-
0.1 mM, 15 min, 78% residual activity in absence of substrate S-pantetheine-3-pyruvate, 33% residual activity in presence of the substrate S-pantetheine-3-pyruvate
5-(N,N-Hexamethylene)amiloride
-
from library of pharmacologically active compounds, LOPAC
8-cyclopentyl-1,3-dipropylxanthine
-
from library of pharmacologically active compounds, LOPAC
Bromopyruvate
-
0.1 mM, 15 min, 2% residual activity in absence of substrate S-pantetheine-3-pyruvate, 76% residual activity in presence of the substrate S-pantetheine-3-pyruvate
cystamine
-
0.1 mM, 15 min, 41% residual activity in absence of substrate S-pantetheine-3-pyruvate, 60% residual activity in presence of the substrate S-pantetheine-3-pyruvate
cystine
-
5 mM, 15 min, 100% residual activity in absence of substrate S-pantetheine-3-pyruvate, 32% residual activity in presence of the substrate S-pantetheine-3-pyruvate
dithiothreitol
-
vanin-1 activity is reduced in the absence of dithiothreitol and in the presence of a high level of 50 mM dithiothreitol
H2O2
-
0.1 mM, 15 min, 17% residual activity in absence of substrate S-pantetheine-3-pyruvate, 47% residual activity in presence of the substrate S-pantetheine-3-pyruvate
N2-(cis-2-aminocyclohexyl)-N6-(3-chlorophenyl)-9-ethyl-9H-purine-2,6-diamine hydrochloride
-
i.e. CGP-74514A hydrochloride, from library of pharmacologically active compounds, LOPAC
NaAsO2
-
1 mM, 15 min, 90% residual activity in absence or presence of substrate S-pantetheine-3-pyruvate
NEM
-
1 mM, 15 min, no residual activity in absence of substrate S-pantetheine-3-pyruvate, 54% residual activity in presence of the substrate S-pantetheine-3-pyruvate
o-Iodosobenzoate
-
0.05 mM, 15 min, 15% residual activity in absence of substrate S-pantetheine-3-pyruvate, 53% residual activity in presence of the substrate S-pantetheine-3-pyruvate
p-aminophenylarsine oxide
-
1 mM, 15 min, 45% residual activity in absence of substrate S-pantetheine-3-pyruvate, 55% residual activity in presence of the substrate S-pantetheine-3-pyruvate
PCMB
-
0.0001 mM, 15 min, 1% residual activity in absence of substrate S-pantetheine-3-pyruvate, 68% residual activity in presence of the substrate S-pantetheine-3-pyruvate
Phenylarsine oxide
-
1 mM, 15 min, 48% residual activity in absence of substrate S-pantetheine-3-pyruvate, 52% residual activity in presence of the substrate S-pantetheine-3-pyruvate
additional information
-
no inhibition by 5 mM GSSG in absence or presence of substrate S-pantetheine-3-pyruvate
-
(R)-2,4-dihydroxy-3,3-dimethyl-N-(3-oxo-4-phenylbutyl)butanamide
i.e. RR6
(R)-2,4-dihydroxy-3,3-dimethyl-N-(3-oxo-4-phenylbutyl)butanamide
i.e. RR6, design, synthesis, and characterization of a novel pantetheine analogue, RR6, that acts as a selective, reversible, and competitive vanin inhibitor at nanomolar concentration. Oral administration of RR6 in rats completely inhibits plasma vanin activity and caused alterations of plasma lipid concentrations upon fasting
4,4'-dithiodipyridine
-
0.01 mM, 15 min, no residual activity in absence of substrate S-pantetheine-3-pyruvate, 13% residual activity in presence of the substrate S-pantetheine-3-pyruvate
iodoacetamide
-
0.1 mM, 15 min, 0.5% residual activity in absence of substrate S-pantetheine-3-pyruvate, 72% residual activity in presence of the substrate S-pantetheine-3-pyruvate
iodoacetate
-
1 mM, 15 min, 16% residual activity in absence of substrate S-pantetheine-3-pyruvate, 90% residual activity in presence of the substrate S-pantetheine-3-pyruvate
pantethine
-
0.01 mM, 15 min, no residual activity in absence of substrate S-pantetheine-3-pyruvate, 52% residual activity in presence of the substrate S-pantetheine-3-pyruvate
RR6
shows high specificity towards vanin 1 and competitively and reversibly inhibits pantetheinase activity at nanomolar concentration
RR6
-
shows high specificity towards vanin 1 and competitively and reversibly inhibits pantetheinase activity at nanomolar concentration
